<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00551304</url>
  </required_header>
  <id_info>
    <org_study_id>TP-020 &amp; TP-039</org_study_id>
    <nct_id>NCT00551304</nct_id>
  </id_info>
  <brief_title>Native Kidney Denervation in Patients With End Stage Renal Disease</brief_title>
  <official_title>Native Kidney Denervation in Patients With End Stage Renal Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the utility of renal denervation in the treatment of patients with End Stage
      Renal Disease (ESRD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To provide confirmation that renal denervation in ESRD patients is safe and feasible.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To provide evidence of denervation, indication of physiologic response, and assess device performance.</measure>
  </secondary_outcome>
  <condition>End Stage Renal Disease</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ardian Catheter</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adult &gt;= 18 years of age

          -  end stage renal disease, undergoing concurrent dialysis treatment

          -  poorly controlled blood pressure on at least 2 antihypertensive drugs

          -  agrees to have the study procedure(s) performed and additional procedures and
             evaluations, including interventions and follow up visits

          -  competent and willing to provide written, informed consent to participate in this
             clinical study.

        Exclusion Criteria:

          -  renal arterial abnormalities

          -  myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within
             six (6) months

          -  hemodynamically significant valvular heart disease

          -  implantable cardioverter defibrillator (ICD) or pacemaker

          -  respiratory support.

          -  pregnant, nursing or planning to be pregnant

          -  other
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Markus Schlaich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Paull II Hosptial</name>
      <address>
        <city>Cracow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2007</study_first_submitted>
  <study_first_submitted_qc>October 26, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2007</study_first_posted>
  <last_update_submitted>November 2, 2012</last_update_submitted>
  <last_update_submitted_qc>November 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2012</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

